drugset / Trial / NCT04035876
Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant
Phase 1/2
Unknown
120 enrolled
Zhejiang University
Huashan Hospital · collabShanghai General Hospital, Shanghai Jiao Tong University School of Medicine · collabShulan (Hangzhou) Hospital · collabThe First Affiliated Hospital of Zhengzhou University · collabThe First Hospital of Jilin University · collabThird Affiliated Hospital, Sun Yat-Sen University · collabTianjin First Central Hospital · collabWest China Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
To assess the primary effects and safety of camrelizumab (SHR-1210) plus apatinib for downstaging/bridging of HCC before liver transplantation.
Timeline
- Start
- 2019-07-16
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |